Stopping Antidepressants

Home > Depression > Stopping Antidepressants

About 31% of people reported discontinuation symptoms after stopping an antidepressant in a 2024 meta-analysis of 79 studies covering 21,002 patients, compared with 17% of people stopping a placebo (Henssler and colleagues, Lancet Psychiatry, 2024). The difference, roughly 15%, is the share attributable to the drug itself, or about one patient in six or seven. Severe symptoms, meaning symptoms that led to dropout or to restarting the medication, occurred in 2.8% after antidepressants and 0.6% after placebo.

Those numbers answer the first question people bring to a stopping conversation, which is whether the symptoms are real. They are, for a minority, and for most of that minority they are brief. The harder questions are whether what you're feeling is withdrawal or returning depression, whether you belong to the group that should keep taking the medication, and how the dose comes down. Each has a reasonably clear evidence base. The depression page covers starting treatment; this page covers ending it.

Discontinuation symptoms are real, and their frequency has been contested

A 2019 systematic review commissioned for a UK parliamentary group pooled 14 studies and reported a weighted incidence of 56%, with 46% of affected people endorsing the most severe rating available (Davies and Read, Addictive Behaviors, 2019). In seven of ten studies with duration data, a meaningful share of people had symptoms for more than two weeks.

A published rebuttal in the same journal argued that the review's selection, extraction, and interpretation were biased, that much of its evidence came from online surveys of self-selected respondents, and that it omitted the placebo-withdrawal comparison, which in some trials produced symptom rates as high as the active drug (Jauhar and Hayes, Addictive Behaviors, 2019). The survey data likely capture people with the worst experiences, while trial data likely under-sample people on medication for many years.

Two meta-analyses have since done what the rebuttal asked for. The 2024 analysis above subtracted placebo rates and arrived at 15%. A 2025 analysis restricted to 50 randomized trials with 17,828 adults found that stopping an antidepressant was associated with about one additional symptom on a standardized checklist at one week, below the four-symptom threshold used to define a clinically significant discontinuation syndrome (Kalfas and colleagues, JAMA Psychiatry, 2025). Dizziness was the most frequent symptom, affecting 6.2% more people than placebo. Notably, both author groups flagged substantial heterogeneity between studies, and trial participants had usually taken medication for months rather than the years common in real-world practice.

The Royal College of Psychiatrists put the clinical conclusion plainly in its 2019 position statement: symptoms are often mild and self-limiting, there is substantial variation between people, and for some they last much longer and are more severe. Most patients will have little trouble; a minority will need a slower plan.

Venlafaxine, desvenlafaxine, and paroxetine are hardest to stop; fluoxetine is easiest

In the 2024 meta-analysis, desvenlafaxine, venlafaxine, imipramine, and escitalopram were associated with higher frequencies of discontinuation symptoms than other antidepressants. Paroxetine's reputation rests on a 1998 randomized trial in which 242 adults in remission on fluoxetine, sertraline, or paroxetine for 4 to 24 months had their medication replaced with placebo for five to eight days (Rosenbaum and colleagues, Biological Psychiatry, 1998). Paroxetine produced the most new somatic and psychological symptoms, sertraline fewer, and fluoxetine very few.

Half-life likely explains most of this pattern. Paroxetine's mean elimination half-life is about 21 hours, according to its FDA label, so blood levels fall by half within a day of a missed dose. Fluoxetine's half-life is 4 to 6 days after chronic dosing, and its active metabolite norfluoxetine persists for 4 to 16 days; the FDA label states that active drug remains in the body for weeks after dosing stops. In effect, fluoxetine tapers itself. Venlafaxine and desvenlafaxine are also short-acting, which is broadly consistent with their position at the top of the list.

The paroxetine label describes the symptom cluster worth knowing: nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances such as electric-shock sensations, tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, and, rarely, hypomania, tinnitus, or seizures. It recommends gradual dose reduction rather than abrupt cessation whenever possible, and it notes that in the generalized anxiety and PTSD trials the dose was lowered by 10 mg per day at weekly intervals before stopping. Importantly, that describes a trial protocol; the right pace for an individual is set with the prescriber.

Discontinuation symptoms and relapse differ in timing and in character

Patients ask me a version of the same question most months: "I was fine for two years, so why do I feel worse three days after my last pill?" The answer is almost always discontinuation, and the timing is the clue. In a systematic review of 61 reports, symptoms typically began within a few days of stopping and lasted a few weeks, including when the dose had been tapered, with later onset and longer persistence possible in a minority (Fava and colleagues, Psychotherapy and Psychosomatics, 2015). The authors warned that these symptoms "may be easily misidentified as signs of impending relapse."

Relapse runs on a different clock. In the 2025 meta-analysis, stopping an antidepressant was not associated with worsening depression scores in the early weeks, even though many participants had major depressive disorder, which led the authors to conclude that depressive symptoms appearing later are indicative of relapse. The 2022 NICE depression guideline makes the same point for patients: relapse does not usually happen as soon as you stop or lower the dose.

Three features separate the two in practice. First, discontinuation symptoms are weighted toward the body: dizziness, nausea, flu-like aches, vivid dreams, and the "zaps." Relapse is weighted toward mood, interest, sleep pattern, and self-regard, and it tends to look like the episode you had before. Second, discontinuation symptoms follow a dose change by hours to days; relapse builds over weeks and often follows a stressor. Third, when the picture is ambiguous, a prescriber may briefly return to the prior dose; the Royal College's statement describes reintroducing the original antidepressant, or a longer-acting drug from the same class, as a standard response to severe symptoms. Discontinuation symptoms generally settle within a day or two of that step. Relapse does not.

Stopping while well roughly doubles the chance of relapse within a year

The best modern estimate comes from the ANTLER trial. Investigators enrolled 478 adults from 150 UK general practices who had been taking citalopram, fluoxetine, sertraline, or mirtazapine, who had either at least two prior depressive episodes or two or more years of treatment, and who felt well enough to consider stopping (Lewis and colleagues, New England Journal of Medicine, 2021). Half continued; half tapered to a matching placebo. At 52 weeks, 39% of the maintenance group and 56% of the discontinuation group had relapsed, a hazard ratio of 2.06. The discontinuation group also reported more symptoms of depression, anxiety, and withdrawal.

Both numbers matter. Stopping raised relapse by 17 percentage points. Yet 44% of people who stopped stayed well for a year without medication, and 39% of people who kept taking it relapsed anyway. The trial gives a patient the real odds on each path.

The older trial literature is broadly consistent with this. A systematic review of 31 randomized continuation trials with 4,410 participants found that staying on an antidepressant after responding reduced the odds of relapse by 70%, with average relapse rates of 41% on placebo and 18% on active treatment (Geddes and colleagues, Lancet, 2003). The protective effect appeared to persist for up to 36 months, although most trials lasted 12. The authors noted that the absolute benefit for an individual depends on that person's absolute risk, which is the principle behind the next section.

Recurrent episodes and severe past episodes argue for staying on longer

Because the relative protection from continuing is similar across risk groups, the people who gain the most in absolute terms are those most likely to relapse. In my practice that means three groups. First, anyone with several prior episodes, since the ANTLER population was selected for recurrent or long-treated depression and still relapsed at 56% within a year of stopping. Second, anyone whose past episode involved hospitalization, suicidal behavior, or psychotic features, where the cost of a recurrence is high enough that even a modest reduction in risk is worth the burden of the medication. Third, anyone with residual symptoms, since "well" in ANTLER meant well enough to consider stopping.

Several situations call for a different conversation entirely. A history of hypomania or a strong family history of bipolar disorder means the antidepressant question sits inside a bipolar evaluation, where stopping and starting antidepressants carries separate risks. A planned or current pregnancy changes the calculus in both directions, and the postpartum depression page covers it. Adolescents need a parent in the room and a plan for the next exam season; the adolescent psychiatry page describes those visits.

For people with a single episode, a full and sustained remission, and a stable life, stopping is reasonable, and I say so. Structured psychotherapy during and after the taper is the one addition I recommend most often; the medication versus therapy page and the CBT page explain what that involves. Whether therapy lowers relapse after discontinuation in any given person is uncertain, and I present it as a judicious hedge rather than a guarantee.

How prescribers taper

Guideline practice shifted after a 2019 analysis of PET imaging data showed that the relationship between SSRI dose and serotonin-transporter occupancy is hyperbolic rather than linear (Horowitz and Taylor, Lancet Psychiatry, 2019). At usual doses, the transporter is already heavily occupied, so halving the dose changes occupancy only modestly. At low doses the curve is steep, and the same milligram reduction produces a much larger pharmacological change. The authors also observed that the two-to-four-week tapers in older guidelines showed minimal benefit over abrupt cessation, and they proposed slow, proportional reductions carried down to very small doses before stopping.

The 2022 NICE depression guideline adopted the core of that logic. It advises prescribers to take the medication's half-life and the duration of treatment into account, to reduce the dose in stages by prescribing a proportion of the previous dose at each step (its example is 50%), to consider smaller proportional reductions (its example is 25%) as the dose becomes lower, to allow one to two weeks after each step to evaluate the effect, and to use liquid preparations when tablets can no longer be divided finely enough. For fluoxetine 20 mg, the guideline notes that alternate-day dosing can serve as a reduction step, which works only because of that drug's long half-life. The Royal College of Psychiatrists' position statement adds that the longer someone has taken an antidepressant, the longer the taper generally should be, and that faster withdrawal may be appropriate after short treatment or with fluoxetine.

In the practice, this translates into a few patterns. People on a short-acting drug such as paroxetine or venlafaxine who have been well for a long time usually come down in proportional steps over months rather than weeks, with the lowest steps taking the longest. When tablets cannot be split small enough, liquid formulations fill the gap. When someone has failed a taper from a short-acting drug more than once, I sometimes switch them to fluoxetine first and then taper that, letting its long half-life smooth the descent. Finally, no reduction is scheduled until the previous one has settled. These are descriptions of what I do with a patient in front of me, and the schedule for any individual is set in that conversation. The medication management page describes how those visits run.

Who this practice fits, and when to go elsewhere

This fits adults and adolescents who have been well on an antidepressant and want a considered plan for coming off, people who tried to stop and ran into symptoms their prescriber dismissed, and people who were told to stay on indefinitely without a clear reason. It also fits people who want a second opinion on whether the medication is still doing anything, which is a different question from whether to stop it.

Some situations belong elsewhere. Depression that has never responded well needs the treatment-resistant depression workup before anyone talks about stopping. Someone in a current episode should be treated, with the stopping question deferred. A pattern of mood elevation, or an antidepressant that has repeatedly made things worse, warrants a bipolar evaluation first. An active suicidal crisis needs an emergency department today.

Cost and booking

Initial evaluations run 60 to 90 minutes and cover the full medication history, prior attempts to stop, and the course of each episode. The practice is out-of-network with all insurance plans. You pay directly and receive a superbill to submit for reimbursement; many NYC plans with out-of-network benefits reimburse a meaningful share once the deductible is met. The numbers are laid out at fees and out-of-network costs, and checking your benefits before the first visit takes about ten minutes. Tapering visits after the evaluation are shorter and spaced to match the reduction schedule.

Bring your current prescription, the dates and doses of every antidepressant you have taken, and notes on any earlier attempt to stop. Schedule a consultation or call (646) 893-4309.

Related

Depression · Medication management · Medication vs therapy vs both · Treatment-resistant depression · Bipolar disorder · Second opinions · What type of doctor treats depression · Emotional blunting on antidepressants · Antidepressant sexual side effects · Antidepressants and weight gain · Depression with ADHD: combining medications · Anxiety medication options · How long antidepressants take to work · Lexapro vs Zoloft · SSRIs for teens · Wellbutrin vs SSRIs

When Depression Becomes an Emergency

The weeks after an antidepressant is reduced or stopped are a time to watch mood closely, because relapse in someone with a history of suicidal thinking can arrive quietly. Suicidal thoughts returning during a taper warrant same-day or next-day contact with your prescriber rather than waiting for the next scheduled step.

Frequently Asked Questions

How common are withdrawal symptoms when stopping antidepressants?

In a 2024 meta-analysis of 79 studies and 21,002 patients, 31% of people reported discontinuation symptoms after stopping an antidepressant and 17% reported them after stopping a placebo. The difference, about 15%, is the share attributable to the medication, roughly one person in six or seven. Severe symptoms occurred in 2.8% after antidepressants and 0.6% after placebo. Older estimates of 56% came from reviews that included online surveys without a placebo comparison.

How can I tell antidepressant withdrawal from relapse?

Timing and character. Discontinuation symptoms arrive within days of a dose change and are mostly physical: dizziness, nausea, electric-shock sensations, flu-like aches, vivid dreams. Relapse builds over weeks, with the same low mood, loss of interest, and hopelessness that brought you to treatment. In randomized trials, stopping was not associated with worsening mood in the first weeks. When the picture is unclear, a prescriber may briefly restore the prior dose; discontinuation symptoms usually settle quickly, relapse does not.

Which antidepressants are hardest to stop?

Desvenlafaxine, venlafaxine, imipramine, and escitalopram were associated with higher rates of discontinuation symptoms in the 2024 meta-analysis. Paroxetine produced the most symptoms in a 1998 trial that interrupted treatment for five to eight days, with sertraline intermediate and fluoxetine causing few. Short half-life explains much of the pattern: paroxetine leaves the body in about a day, while fluoxetine and its active metabolite persist for weeks, which smooths the decline on its own.

What is the chance depression comes back if I stop?

In the ANTLER trial of 478 adults who felt well on long-term antidepressants, 56% of those who tapered to placebo relapsed within 52 weeks, compared with 39% of those who continued. Across 31 older trials, relapse averaged 41% on placebo and 18% on continued medication. People with several prior episodes, severe past episodes, or residual symptoms carry the highest risk and gain the most from staying on.

How long does tapering an antidepressant take?

It varies with the drug, the dose, how long you have taken it, and how you respond to each reduction. Standard two-to-four-week tapers show little advantage over abrupt stopping in the published evidence, so prescribers increasingly reduce in proportional steps over months, slowing down at low doses where each milligram matters more. Fluoxetine can usually come down faster. The pace is set with your prescriber and adjusted as you go.

Can I stop my antidepressant on my own?

Stopping abruptly is the pattern most associated with discontinuation symptoms in FDA labeling and in the trial literature, and stopping without a plan is also when relapse goes unrecognized. Antidepressants are not habit-forming in the way sedatives or opioids are, and most people who want to stop can. The safer route is a scheduled conversation with the prescriber about whether now is the right time and how the dose will come down.

Sources

1. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(7):526–535. PMID 38851198
2. Kalfas M, Tsapekos D, Butler M, et al. Incidence and nature of antidepressant discontinuation symptoms: a systematic review and meta-analysis. JAMA Psychiatry. 2025;82(9):896–904. PMID 40632531
3. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav. 2019;97:111–121. PMID 30292574
4. Jauhar S, Hayes J. The war on antidepressants: what we can, and can't conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read. Addict Behav. 2019;97:122–125. PMID 30732861
5. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77–87. PMID 9646889
6. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72–81. PMID 25721705
7. Lewis G, Marston L, Duffy L, et al. Maintenance or discontinuation of antidepressants in primary care (ANTLER). N Engl J Med. 2021;385(14):1257–1267. PMID 34587384
8. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–661. PMID 12606176
9. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538–546. PMID 30850328
10. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline NG222. 2022. Section 1.4, stopping antidepressant medication. nice.org.uk/guidance/ng222
11. Royal College of Psychiatrists. Position statement on antidepressants and depression. PS04/19. May 2019. rcpsych.ac.uk
12. U.S. Food and Drug Administration. PAXIL (paroxetine) prescribing information, revised 8/2023. Sections 5.7 (Discontinuation Syndrome) and 12.3 (Pharmacokinetics). accessdata.fda.gov
13. U.S. Food and Drug Administration. PROZAC (fluoxetine) prescribing information. Clinical Pharmacology (accumulation and slow elimination) and Discontinuation of Treatment with Prozac. accessdata.fda.gov